Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

NCT07032727 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT07032727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07032727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
September 12, 2025
Completion date
June 1, 2029
Enrollment
68 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

idh1-mutated malignancies, mutations, targeted therapy